A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of [225Ac]Ac-PSMA-XT Injection in Patients With Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-Resistant Prostate Cancer Patients
Investigational drug(s) / intervention(s)
225Ac-PSMA-XT
225Ac-PSMA-XT: Patients will receive 225Ac-PSMA-XT administration at an interval of 6 weeks between each dose.
Study summary
The purpose of this study is to determine the safety and efficacy of 225Ac -labeled PSMA ligand(PSMA-XT) in the treatment of mCRPC
Eligibility
Sex
MALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. have the ability to understand and sign an approved informed consent form (ICF).
2. \>= 18 years old.
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
4. have a life expectancy \>6 months.
5. have histological, pathological, and/or cytological confirmation of prostate cancer.
6. PSMA Positron Emission Tomography (PET)/Computed Tomography (CT) scan positive
7. have a castrate level of serum/plasma testosterone (\<50 ng/dL or \<1.7 nmol/L).
8. have received at least one NAAD (such as enzalutamide and/or abiraterone)； patients must have been previously treated undergone at least 1-2 prior taxane-based chemotherapy regimens or be unsuitable for taxane therapy (unsuitability includes contraindications, investigator-determined ineligibility, or patient refusal) in mCRPC stage.
9. progressive mCRPC.
10. have adequate organ function。
11. Subjects of childbearing potential voluntarily use an effective method of contraception, such as condoms, oral or injectable contraceptives, Intra-uterine device（IUD）,etc., during treatment and within 6 months of the last use of the trial drug.
Exclusion Criteria:
1. Previous treatment with any of the following within 6 months of enrollment: Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, hemi-body irradiation. Previous PSMA-targeted radioligand therapy is not allowed.
Known other malignancies.
2. Any systemic anti-cancer therapy (e.g. chemotherapy, immunotherapy or biological therapy within 28 days prior to day of enrollment.
3. Known hypersensitivity to the components of the study therapy or its analogs.
4. A superscan as seen in the baseline bone scan.
5. Patients with a history of Central Nervous System (CNS) metastases.
6. Uncontrolled, intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, cardiac arrhythmia, or other severe complications.
Primary outcome measure(s)
Treatment emergent adverse events — Through study completion, assessed up to 2 years To evaluate the safety and tolerability of \[177Lu\]Lu-PSMA-XT Injection assessed from the number and incidence of patients with adverse events using CTCAE v5.0 and physical examination, electrocardiogram and laboratory abnormality, etc.
Dose-limiting toxicity（DLT） — Through study completion, assessed up to 2 years Incidence and severity of dose-limiting toxicities.
Trial sites (1)
Facility
City
Region
Status
Cancer Hospital of Shandong First Medical University
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.